Memorial Sloan Kettering hematologic oncologist Urvi Shah

Urvi A. Shah, MD

Hematologic Oncologist

Titles

Assistant Attending Physician

Clinical Expertise

Multiple Myeloma; Smoldering Myeloma; Monoclonal Gammopathy of Undetermined Significance (MGUS); Related Plasma Cell Disorders

Share

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Monday through Friday, 8:00 a.m. to 6:00 p.m., (Eastern time)
Accepted Insurance Providers

Dr. Shah accepts the following list of insurance providers. Select your insurance provider to see more details.

Aetna

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (City of NY retirees only, starting 7/1/23)

Payor Type:
In Network Coverage Type(s): PPO

Blue Cross Blue Shield Federal Employee Program

Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO

Blue Cross Blue Shield New York

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS

Blue Cross Health Plus

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Carrum Health

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

Cigna

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Connecticare

Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO

Emblem

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Emblem Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Emblem Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO

Empire Blue Cross Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO, DSN

Empire Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Fidelis

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO

Fidelis Managed Medicaid & HARP

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Fidelis Medicare Advantage

Payor Type:
In Network Coverage Type(s): HMO

First Health

Payor Type:
In Network Coverage Type(s): PPO

Healthfirst

Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS

Healthfirst Managed Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Healthfirst Medicare Advantage

Payor Type:
In Network Coverage Type(s): HMO, PPO

Healthsmart

Payor Type: Commercial
In Network Coverage Type(s): PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

Payor Type: Commercial
In Network Coverage Type(s): HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO

Husky CT Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Magnacare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO

Medicare Part A&B (traditional Medicare)

Payor Type:
In Network Coverage Type(s): Federal Government

Multiplan/Beech Street/PHCS

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

MVP

Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP

Non-Participating Plans with Out of Network Benefits

Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

Payor Type:
In Network Coverage Type(s): TBD

Oscar

Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO

Oxford

Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO

Qualcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Straight NJ Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Straight NY Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Tricare

Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO

UMR

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS

United Healthcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

World Trade Center Health Program (WTC)

Payor Type: Commercial
In Network Coverage Type(s): State Government

Contact and Location

Locations map
Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.

See all locations

About Me

Education

MD, Grant Medical College

Residencies

Internal Medicine - Tufts Medical Center

Fellowships

Adult Cancer Immunotherapy - Memorial Sloan Kettering Cancer Center; Hematology and Medical Oncology - Montefiore Medical Center & Albert Einstein College of Medicine

Board Certifications

Internal Medicine; Medical Oncology; Hematology

I am a board-certified hematologic-oncologist with expertise in diagnosing and treating plasma cell disorders. These include multiple myeloma, smoldering myeloma, and monoclonal gammopathy of undetermined significance (MGUS), among others. At Memorial Sloan Kettering Cancer Center (MSK), I work as part of a multidisciplinary team that cares for people with these cancers.

Read more

During my oncology fellowship training, I needed chemotherapy for Hodgkin lymphoma. My firsthand experience on the other side of the doctor-patient relationship has helped me relate to patients in a more compassionate and empathic way. I find that clear, effective communication with patients, family members, and doctors can be crucial to prevent unnecessary stress and help with recovery.

I conduct clinical and translational research on plasma cell disorders and am currently involved in several clinical trials that are developing and testing new treatments. At MSK, our patients have access to the latest treatments, including immune-based therapies for plasma cell disorders. Sometimes this access is achieved through a clinical trial, but it can also be part of our standard care. I value patients’ goals for their cancer treatment very strongly. I work closely with them to come up with a care plan that suits their needs and also allows for the best possible treatment strategy.

I believe it is important to treat patients with a holistic approach. Therefore, my research focuses on studying the effect of modifiable risk factors (such as nutrition, obesity, and diabetes) on cancer development or progression (most specifically myeloma). I lead the NUTRIVENTION (nutrition intervention) trials, through which we study the impact of dietary interventions and supplements in plasma cell disorders. We study how these interventions influence insulin resistance, body composition, the gut microbiome, and the immune system to reduce the risk of cancer progression and improve outcomes.

In my free time, I enjoy painting with mixed media, cooking, staying active, and being outdoors, especially hiking trails around New York City.

 

I find that clear, effective communication with patients, family members, and doctors can be crucial to prevent unnecessary stress and help in recovery.

-Dr. Shah

Awards and Honors

  • American Society of Hematology Scholar Award (2023-2025)
  • Castle Connolly: America's Top Doctors (2023)
  • Rising Star Award, Castle Connolly (2021, 2022)
  • Paul Calabresi K12 Career Development Award for Clinical Oncology, NCI (2021-2024)
  • Career Development Award, International Myeloma Society (2021-2023)
  • Transdisciplinary Research on Energetics and Cancer (TREC) Training Workshop, National Cancer Institute (NCI, 2021)
  • Clinical Research Training Institute (CRTI) Award, ASH (2020)
  • Future Leaders in Hematology Award, Celgene (2019)
  • Shark Tank Audience Choice Award, Memorial Sloan Kettering Cancer Center (2019)
  • Henry L. Moses Prize for Best Clinical Paper, Montefiore Medical Center (2019)
  • ASCO/AACR Methods in Clinical Cancer Research Workshop (2018)
  • Second Place, Outstanding Fellow Research Award, Albert Einstein College of Medicine and Montefiore Medical Center Research Symposium (2018)
  • American Society of Hematology (ASH) Abstract Achievement Award (2017)
  • ECOG-ACRIN Young Investigator Symposium Distinction Award for Translational Research (2017)
  • Chief Fellow, Hematology Rotation, Montefiore Medical Center (2017)
  • Outstanding Emergency Department Resident Award, Tufts Medical Center (2015)

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Myeloma Service doctors

Clinical Trials

Read more
Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Shah UA, Maclachlan KH, Derkach A, Salcedo M, Barnett K, Caple J, Blaslov J, Tran L, Ciardiello A, Burge M, Shekarkhand T, Adintori P, Cross J, Pianko MJ, Hosszu K, McAvoy D, Mailankody S, Korde N, Hultcrantz M, Hassoun H, Tan CR, Lu SX, Patel D, Diamond B, Shah G, Scordo M, Lahoud O, Chung DJ, Landau H, Usmani SZ, Giralt S, Taur Y, Landgren CO, Block G, Block T, Peled JU, van den Brink MRM, Lesokhin AM. Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets. Clinical Cancer Research. 2022

Malik M, Sweeney NW, Jafri M, Derkach A, Chmielewski C, Adintori PA, Mailankody S, Korde N, Tan CR, Hassoun H, Hultcrantz M, Hillengass J, McCann SE, Iyengar N, Usmani S, Giralt SA, Landgren O, van den Brink MRM, Ahlstrom J, Lesokhin AM, D’Souza AD, Chimonas S, Shah UA. Nutrition perceptions, needs and practices among patients with plasma cell disorders. Blood Cancer J. 2022, Apr. PMCID: PMC9021216

Shah UA*, Rögnvaldsson S*, Derkach A, Björkholm M, Turesson I, David Y, Hultcrantz M, Tan C, Hassoun H, Korde N, Lesokhin A, Mailankody S, Kristinsson SY, Landgren CO. Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controlsHaematologica. 2021 Sep; PMCID: PMC8719074

Read more

Shah UA, Iyengar N. Plant-Based and Ketogenic Diets As Diverging Paths to Address Cancer: A Review. JAMA Oncol. 2022 Aug 1;8(8):1201-1208

Shah UA. Cancer and coronavirus disease 2019 (COVID-19) - Facing the “C words.” JAMA Oncology. 2020 Sep;6:1330-1331. 

Shah UA, Chung E, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat T, Mai Y, Wei Y, Ishida E, Choudhary G, Joseph A, Rice R, Gitego N, Bartenstein M, Goel S, Mantzaris I, Shastri A, Parrish C, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S, Verma V, Ye BH, Janakiram M. North American ATLL has a Distinct Mutational and Transcriptional Profile and responds to epigenetic therapies. Blood 2018 Aug 13, PMID: 30104217.

Publications on PubMed

Visit PubMed for a full listing of Dr. Shah’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Urvi A. Shah discloses the following relationships and financial interests:

  • American Society of Clinical Oncology (ASCO)
    Provision of Services (uncompensated)
  • Association of Community Cancer Centers
    Provision of Services
  • Hospital Sirio-Libanes
    Provision of Services
  • Intellisphere, LLC
    Provision of Services
  • Janssen Scientific Affairs, LLC
    Provision of Services
  • MJH Life Sciences
    Provision of Services
  • Mashup Media, LLC
    Provision of Services
  • Myeloma Crowd
    Provision of Services (uncompensated)
  • Plant Powered Metro New York
    Provision of Services (uncompensated)

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures